[ad_1]
On Tuesday, JPMorgan adjusted its stance on Biomea Fusion Inc. (NASDAQ:BMEA), downgrading the inventory from Chubby to Impartial and slashing the share worth goal considerably to $14.00 from the earlier $51.00.
The choice comes after reviewing the corporate’s fourth-quarter outcomes, which included a per-share lack of $0.98, and the early information from the COVALENT-112 examine regarding BMF-219, a possible remedy for Kind 1 diabetes (T1D).
The preliminary information from the examine, which concerned a small affected person pattern of simply two people, offered challenges in interpretation attributable to various baseline histories and on-treatment follow-up by dose power and period. Though there was a reported enhance within the C-peptide index AUC starting from +12% to +40% over weeks 4 to eight, JPMorgan famous the shortage of baseline C-peptide indices, making it tough to find out the medical significance of those adjustments.
Additional complicating the outlook for BMF-219 is the blended information from the COVALENT-111 examine for Kind 2 diabetes (T2D), which indicated a free correlation between the drug’s pharmacokinetics and HbA1c ranges however raised questions relating to dose responsiveness. This has led to skepticism concerning the drug’s mechanism of motion, its sturdiness, and the scale of the affected person inhabitants it might serve.
JPMorgan anticipates that solutions to the excellent questions surrounding BMF-219 won’t be obtainable till the second half of 2024. Moreover, the agency highlighted issues about Biomea Fusion’s monetary runway, which is estimated to final lower than 12 months, as famous within the firm’s 2023 10-Ok submitting with a going concern.
The analyst additionally identified that Biomea Fusion’s acute myeloid leukemia (AML) program is trailing behind its rivals, with the number of a beneficial section 2 dose (RP2D) anticipated later within the 12 months.
Given these components, JPMorgan expects Biomea Fusion’s inventory to commerce inside a decent vary within the close to to midterm, prompting the downgrade to a Impartial score.
This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.
[ad_2]
Source link
